Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Docetaxel/Cisplatin and Gemcitabine/Cisplatin in Advanced NSCLC
NCT00270582Phase 2Unknown
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of docetaxel, cisplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Far Eastern Memorial Hospital. Primary endpoint: 1-Year Treatment Failure Rate. Status: unknown.
02
Drugs
docetaxelcisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00270582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270582.